Garnet BioTherapeutics Inc.

Garnet BioTherapeutics has developed a distinct population of "smart" bone-marrow derived cells capable of reducing inflammation and promoting healing. The firm also boasts a proprietary scalable cell expansion technology that can generate billions of patient doses of GBT009 from a single bone marrow donor, the company claims. The company plans to develop therapies to reduce scarring and accelerate healing in post-surgical wound repair and other dermatology applications. It may eventually expand into additional reconstructive and surgical procedures.